130309-46-5

Basic information

• Product Name: 4-(BOC-AMINO)CYCLOHEXANECARBOXYLIC ACID
• Synonyms: 4-(BOC-AMINO)CYCLOHEXANECARBOXYLIC ACID;4-N-BOC-AMINOCYCLOHEXANE CARBOXYLIC ACID;4-TERT-BUTOXYCARBONYLAMINO-CYCLOHEXANECARBOXYLIC ACID;4-(tert-Butoxycarbonylamino)cyclohexanecarboxylic Acid (cis- and trans- mixture);1-(t-Butyloxycarbonylamino)cyclohexyl-4-carboxylic acid;4-[(tert-Butoxycarbonyl)amino]cyclohexane-1-carboxylic acid;4-Aminocyclohexane-1-carboxylic acid, N-BOC protected;Cyclohexanecarboxylicacid, 4-[[(1,1-dimethylethoxy)carbonyl]amino]-
• CAS NO: 130309-46-5
• Molecular Formula: C₁₂H₂₁NO₄
• Molecular Weight: 243.3
• Mol File: 130309-46-5.mol
• Article Data: 27

Chemical Properties

• Boiling Point: 396.7 °C at 760 mmHg
• Flash Point: 193.7 °C
• Appearance: /
• Density: 1.12
• Vapor Pressure: 2.12E-07mmHg at 25°C
• Refractive Index: 1.493
• Storage Temp.: 2-8°C
• Solubility: Soluble in methanol and tetrahydrofuran(THF).
• PKA: 4.76±0.10(Predicted)
• CAS DataBase Reference: 4-(BOC-AMINO)CYCLOHEXANECARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(BOC-AMINO)CYCLOHEXANECARBOXYLIC ACID(130309-46-5)
• EPA Substance Registry System: 4-(BOC-AMINO)CYCLOHEXANECARBOXYLIC ACID(130309-46-5)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 130309-46-5(Hazardous Substances Data)

Usage

Uses

4-(Boc-amino)cyclohexanecarboxylic acid is used as pharmaceutical intermediate.

InChI:InChI=1/C12H21NO4/c1-12(2,3)17-11(16)13-9-6-4-8(5-7-9)10(14)15/h8-9H,4-7H2,1-3H3,(H,13,16)(H,14,15)

Upstream product

• 503817-57-0 methyl 4-{[(tert-butoxy)carbonyl]amino}cyclohexane-1-carboxylate 
• 175867-59-1 methyl 4-aminocyclohexane-1-carboxylate 
• 6297-22-9 4-carbomethoxycyclohexanone 
• 874-61-3 4-oxocyclohexanecarboxylic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1776-53-0 4-aminocyclohexanecarboxylic acid 
• 77-92-9 citric acid 
• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 
• 38446-95-6 4-oxocyclohexanecarboxylic acid tert-butyl ester 
• 400899-07-2 methyl (1r,4r)‐4‐{[(tert‐butoxy)carbonyl](methyl)amino}cyclohexane‐1‐carboxylate 
• 881657-40-5 tert-butyl ((3R,6S)-6-formyltetrahydro-2H-pyran-3-yl)carbamate 
• 603130-12-7 1,5-anhydro-2-[(tert-butoxycarbonyl)amino]-2,3,4-trideoxy-D-erythro-hexitol 
• 146307-51-9 methyl (1R,4R)-4-((tert-butoxycarbonyl)amino)cyclohexane-1-carboxylate 
• 150-13-0 4-amino-benzoic acid 

Downstream Products

• 239074-29-4 trans (4-hydroxymethyl-cyclohexyl)-carbamic acid tert-butyl ester 
• 944404-27-7 [trans-4-(4-isopropyl-piperazine-1-carbonyl)-cyclohexyl]-carbamic acid tert-butyl ester 
• 1401729-07-4 (4-{N'-[4-(2-ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-ylmethyl)benzoyl]hydrazinocarbonyl}cyclohexyl)carbamic acid tert-butyl ester 
• 62456-15-9 methyl trans-4-amino-cyclohexanecarboxylate 
• 609780-77-0 tert-butyl 4-[{[4-(aminocarbonyl)-phenyl]amino}carbonyl]cyclohexylcarbamate 
• 181308-53-2 {4-[(E)-Benzylimino-methyl]-cyclohexyl}-carbamic acid tert-butyl ester 
• 878395-72-3 4-amino-cyclohexanecarboxylic acid [2-(cyclopentanecarbonyl-amino)-benzothiazol-6-yl]-amide 

Relevant articles and documents

Rigid aromatic linking moiety in cationic lipids for enhanced gene transfection efficiency

Although numerous cationic lipids have been developed as non-viral gene vectors, the structure-activity relationship (SAR) of these materials remains unclear and needs further investigation. In this work, a series of lysine-derived cationic lipids contain

Preparation method of trans 4 - (tert-butyloxycarbonylamino) cyclohexanecarboxylic acid and intermediate thereof

The invention provides a preparation method of trans 4 - (tert-butyloxycarbonylamino) cyclohexanecarboxylic acid and an intermediate thereof. The preparation method is characterized by comprising the following steps of 4 - oxocyclohexane carboxylic ester and chiral ligand reagent tert-butyl sulfinamide as a raw material, reducing amination to obtain trans -4 -tert-butyl sulfinyl sulfenamide cyclohexane carboxylic acid ester by virtue of chiral ligand reagent tert-butyl sulfinamide and 4 - 95% -oxocyclohexane carboxylic ester, and is stable in basic conditions and easy to leave under an acidic condition. Reaction conditions are mild, operation is simple and convenient, yield is high, and industrial production is easy.

Compound serving as protein kinase inhibitor and application of compound

The invention discloses a compound used as a protein kinase inhibitor and application of the compound, the compound has an obvious inhibition effect on protein kinase activity, can be used as a BTK inhibitor for preparing medicines for treating BTK-mediated diseases such as malignant tumors, autoimmune diseases and the like, and has wide application prospect.

Generation of highly potent DYRK1A-dependent inducers of human β-Cell replication via Multi-Dimensional compound optimization

Small molecule stimulation of β-cell regeneration has emerged as a promising therapeutic strategy for diabetes. Although chemical inhibition of dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) is sufficient to enhance β-cell replicat